All stocks / OTLC
Oncotelic Therapeutics, Inc. OTLC
Oncotelic Therapeutics (OTLC): convertible notes mentioned in an 8-K in August 2026, a late 10-K notice in March 2026 and the latest annual figures in plain language. Each fact links to its SEC filing.
Market listing
- Full name
- ONCOTELIC THERAPEUTICS INC
- Market tier
- OTCQB
- Trading status
- Active
- Last trade
- Nov 16
News headlines
The financial report, and what it means
Annual figures to 2025-12-31- Net income
- $249,279,832
It earned more than it spent
SteadyAfter all costs, the company kept $249.3 million as profit in the year.
- Cash and cash equivalents
- $88,857
- Net cash used in operating activities
- ($1,383,145)
The cash could run out soon
Under strainIt had $88,857 in the bank and used about $115,262 a month. At that pace the money lasts less than a month unless it borrows or sells more shares.
- Total assets
- $393,088,242
- Total liabilities
- $131,356,683
It owns more than it owes
SteadyEverything the company owns adds up to $393.1 million. Its debts and unpaid bills add up to $131.4 million. That is about $0.33 owed for every $1 owned.
What this adds up to
1 of 3 checks show strain. The cash could run out soon. These are facts from the company's own reports, not a recommendation.
Signals
Estimated float about 361,652,650 shares as of 2026-11-13: 457,512,796 outstanding minus 95,860,146 held by 2 reporting insider(s).
Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record
8-K filed 2026-08-04 mentions: convertible note.
Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record
8-K filed 2026-06-29 mentions: convertible note.
Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record
Filed NT 10-K on 2026-03-31: notice that a periodic report is late.
Rule: Late-filing notice (Form NT 10-K or NT 10-Q) in the last 12 months. Source record
8-K filed 2026-01-29 mentions: convertible note.
Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record
8-K filed 2026-01-07 mentions: equity line.
Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record
8-K filed 2026-01-06 mentions: equity line.
Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record
Shares outstanding
Source: SEC filingsPrice chart
Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets
Recent filings
Common questions about OTLC
Does OTLC file reports with the SEC?
Yes. Oncotelic Therapeutics files with the SEC under company number 0000908259. The most recent filing we hold is a 10-Q dated 2026-11-16.
Source recordHow many OTLC shares are outstanding?
457,512,796 shares as of 2026-11-13, as reported to the SEC.
Source recordHas OTLC filed reports late?
Yes. In the last 12 months it filed 1 late-filing notice, most recently a NT 10-K on 2026-03-31. A notice means a report was not ready on time; check whether the report followed.
Source recordWho runs Oncotelic Therapeutics?
Officers named in its insider filings: Seymour Howard Fein (CRO/CMO), Anthony E Maida Iii (DIRECTOR AND CMO - TRANS. MED.) and Saran Saund (CBO).
Source recordIs Oncotelic Therapeutics making money?
After all costs, the company kept $249.3 million as profit in the year. (Annual figures to 2025-12-31. Facts from the company's own report, not a recommendation.)
Source record